A number of firms have modified their ratings and price targets on shares of Tetraphase Pharmaceuticals (NASDAQ: TTPH) recently:

  • 8/10/2017 – Tetraphase Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/9/2017 – Tetraphase Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.25 price target on the stock. According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
  • 7/27/2017 – Tetraphase Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 7/26/2017 – Tetraphase Pharmaceuticals was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock, up previously from $8.00.
  • 7/26/2017 – Tetraphase Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $13.00 price target on the stock, up previously from $12.00.
  • 7/11/2017 – Tetraphase Pharmaceuticals is now covered by analysts at HC Wainwright. They set a “buy” rating and a $15.00 price target on the stock.
  • 7/6/2017 – Tetraphase Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

Tetraphase Pharmaceuticals, Inc. (NASDAQ TTPH) opened at 5.65 on Tuesday. The company’s market cap is $288.45 million. The firm’s 50-day moving average is $6.91 and its 200 day moving average is $7.00. Tetraphase Pharmaceuticals, Inc. has a 1-year low of $3.11 and a 1-year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. During the same quarter in the previous year, the firm posted ($0.47) EPS. Tetraphase Pharmaceuticals’s revenue was up 28.2% on a year-over-year basis. Analysts predict that Tetraphase Pharmaceuticals, Inc. will post ($2.55) earnings per share for the current fiscal year.

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.